Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.
Pancreas Neoplasm|Stomach Neoplasm|Gastrointestinal Neoplasms|Digestive System Neoplasm|Neoplasms by Site|Neoplasms
DRUG: EO-3021
The incidence rate of dose limiting toxicities (DLT) during the first 21-day cycle of EO-3021 treatment, The first 21-day treatment cycle for each patient enrolled in the Escalation Phase|Number of patients with treatment emergent adverse events, From the time of informed consent, for approximately 12 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)|Number of patients with serious adverse events, From the time of informed consent, for approximately 12 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)|Number of patients with clinically significant changes to vital signs, From the time of informed consent, for approximately 12 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose|Number of patients with clinically significant changes in laboratory tests, From the time of informed consent, for approximately 12 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.